Please login to the form below

Not currently logged in


This page shows the latest MSD news and features for those working in and with pharma, biotech and healthcare.

Keytruda doubles five-year survival rate in NSCLC

Keytruda doubles five-year survival rate in NSCLC

Merck reveals long-term efficacy data for blockbuster immunotherapy. Merck &Co/MSD’s Keytruda (pembrolizumab) doubled the five-year survival rate for patients with metastatic non-small cell lung cancer (NSCLC)

Latest news

More from news
Approximately 63 fully matching, plus 360 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 4 fully matching, plus 33 partially matching documents found.

Latest appointments

More from appointments
Approximately 5 fully matching, plus 48 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 18 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
11 London

11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...